KEWAUNEE SCIENTIFIC CP (KEQU) Stock Fundamental Analysis

NASDAQ:KEQU • US4928541048

42.55 USD
+1 (+2.41%)
Last: Feb 20, 2026, 08:00 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to KEQU. KEQU was compared to 185 industry peers in the Health Care Equipment & Supplies industry. KEQU has an average financial health and profitability rating. KEQU has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • KEQU had positive earnings in the past year.
  • KEQU had a positive operating cash flow in the past year.
  • In multiple years KEQU reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: KEQU reported negative operating cash flow in multiple years.
KEQU Yearly Net Income VS EBIT VS OCF VS FCFKEQU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M 15M

1.2 Ratios

  • KEQU has a better Return On Assets (6.21%) than 85.95% of its industry peers.
  • KEQU's Return On Equity of 16.81% is amongst the best of the industry. KEQU outperforms 92.97% of its industry peers.
  • KEQU has a Return On Invested Capital of 10.67%. This is amongst the best in the industry. KEQU outperforms 91.35% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for KEQU is in line with the industry average of 8.75%.
  • The last Return On Invested Capital (10.67%) for KEQU is above the 3 year average (9.90%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 6.21%
ROE 16.81%
ROIC 10.67%
ROA(3y)6.79%
ROA(5y)2.22%
ROE(3y)17.94%
ROE(5y)5.55%
ROIC(3y)9.9%
ROIC(5y)N/A
KEQU Yearly ROA, ROE, ROICKEQU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 30

1.3 Margins

  • KEQU has a better Profit Margin (4.11%) than 75.14% of its industry peers.
  • KEQU has a better Operating Margin (6.89%) than 71.35% of its industry peers.
  • With a Gross Margin value of 29.09%, KEQU is not doing good in the industry: 75.68% of the companies in the same industry are doing better.
  • In the last couple of years the Gross Margin of KEQU has grown nicely.
Industry RankSector Rank
OM 6.89%
PM (TTM) 4.11%
GM 29.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.96%
GM growth 5Y12.54%
KEQU Yearly Profit, Operating, Gross MarginsKEQU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so KEQU is still creating some value.
  • KEQU has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, KEQU has more shares outstanding
  • Compared to 1 year ago, KEQU has a worse debt to assets ratio.
KEQU Yearly Shares OutstandingKEQU Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M 2M 2.5M
KEQU Yearly Total Debt VS Total AssetsKEQU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • KEQU has an Altman-Z score of 3.36. This indicates that KEQU is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.36, KEQU is in the better half of the industry, outperforming 71.35% of the companies in the same industry.
  • KEQU has a debt to FCF ratio of 12.32. This is a negative value and a sign of low solvency as KEQU would need 12.32 years to pay back of all of its debts.
  • KEQU has a Debt to FCF ratio of 12.32. This is in the better half of the industry: KEQU outperforms 71.89% of its industry peers.
  • KEQU has a Debt/Equity ratio of 0.85. This is a neutral value indicating KEQU is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.85, KEQU is not doing good in the industry: 73.51% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF 12.32
Altman-Z 3.36
ROIC/WACC1.06
WACC10.04%
KEQU Yearly LT Debt VS Equity VS FCFKEQU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 2.48 indicates that KEQU has no problem at all paying its short term obligations.
  • KEQU has a Current ratio (2.48) which is comparable to the rest of the industry.
  • A Quick Ratio of 1.71 indicates that KEQU should not have too much problems paying its short term obligations.
  • KEQU's Quick ratio of 1.71 is in line compared to the rest of the industry. KEQU outperforms 45.95% of its industry peers.
Industry RankSector Rank
Current Ratio 2.48
Quick Ratio 1.71
KEQU Yearly Current Assets VS Current LiabilitesKEQU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

3

3. Growth

3.1 Past

  • KEQU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.55%.
  • The Revenue has grown by 43.02% in the past year. This is a very strong growth!
  • The Revenue has been growing by 10.27% on average over the past years. This is quite good.
EPS 1Y (TTM)-37.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.15%
Revenue 1Y (TTM)43.02%
Revenue growth 3Y12.5%
Revenue growth 5Y10.27%
Sales Q2Q%46.76%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KEQU Yearly Revenue VS EstimatesKEQU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
KEQU Yearly EPS VS EstimatesKEQU Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 0.5 1 1.5

5

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 8.43, the valuation of KEQU can be described as very reasonable.
  • 96.76% of the companies in the same industry are more expensive than KEQU, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 26.99, KEQU is valued rather cheaply.
Industry RankSector Rank
PE 8.43
Fwd PE N/A
KEQU Price Earnings VS Forward Price EarningsKEQU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of KEQU indicates a rather cheap valuation: KEQU is cheaper than 97.30% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of KEQU indicates a rather cheap valuation: KEQU is cheaper than 87.03% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 23.85
EV/EBITDA 6.5
KEQU Per share dataKEQU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80

4.3 Compensation for Growth

  • The decent profitability rating of KEQU may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

  • KEQU does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

KEWAUNEE SCIENTIFIC CP

NASDAQ:KEQU (2/20/2026, 8:00:01 PM)

42.55

+1 (+2.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)12-10
Earnings (Next)03-11
Inst Owners41.13%
Inst Owner Change3.66%
Ins Owners15.89%
Ins Owner Change-3.83%
Market Cap122.12M
Revenue(TTM)285.51M
Net Income(TTM)11.74M
Analysts82.86
Price TargetN/A
Short Float %1.58%
Short Ratio5.38
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 8.43
Fwd PE N/A
P/S 0.43
P/FCF 23.85
P/OCF 14.09
P/B 1.75
P/tB 3.03
EV/EBITDA 6.5
EPS(TTM)5.05
EY11.87%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.78
FCFY4.19%
OCF(TTM)3.02
OCFY7.1%
SpS99.48
BVpS24.34
TBVpS14.04
PEG (NY)N/A
PEG (5Y)N/A
Graham Number52.59
Profitability
Industry RankSector Rank
ROA 6.21%
ROE 16.81%
ROCE 13.73%
ROIC 10.67%
ROICexc 11.69%
ROICexgc 15.07%
OM 6.89%
PM (TTM) 4.11%
GM 29.09%
FCFM 1.79%
ROA(3y)6.79%
ROA(5y)2.22%
ROE(3y)17.94%
ROE(5y)5.55%
ROIC(3y)9.9%
ROIC(5y)N/A
ROICexc(3y)12.02%
ROICexc(5y)N/A
ROICexgc(3y)13.16%
ROICexgc(5y)N/A
ROCE(3y)12.97%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.96%
GM growth 5Y12.54%
F-Score4
Asset Turnover1.51
Health
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF 12.32
Debt/EBITDA 2.29
Cap/Depr 56.58%
Cap/Sales 1.24%
Interest Coverage 250
Cash Conversion 33.42%
Profit Quality 43.61%
Current Ratio 2.48
Quick Ratio 1.71
Altman-Z 3.36
F-Score4
WACC10.04%
ROIC/WACC1.06
Cap/Depr(3y)110.02%
Cap/Depr(5y)97.64%
Cap/Sales(3y)1.65%
Cap/Sales(5y)1.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.15%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)43.02%
Revenue growth 3Y12.5%
Revenue growth 5Y10.27%
Sales Q2Q%46.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1290.93%
FCF growth 3YN/A
FCF growth 5Y49.49%
OCF growth 1Y51.55%
OCF growth 3YN/A
OCF growth 5Y28.86%

KEWAUNEE SCIENTIFIC CP / KEQU FAQ

What is the ChartMill fundamental rating of KEWAUNEE SCIENTIFIC CP (KEQU) stock?

ChartMill assigns a fundamental rating of 5 / 10 to KEQU.


What is the valuation status of KEWAUNEE SCIENTIFIC CP (KEQU) stock?

ChartMill assigns a valuation rating of 5 / 10 to KEWAUNEE SCIENTIFIC CP (KEQU). This can be considered as Fairly Valued.


How profitable is KEWAUNEE SCIENTIFIC CP (KEQU) stock?

KEWAUNEE SCIENTIFIC CP (KEQU) has a profitability rating of 6 / 10.


How financially healthy is KEWAUNEE SCIENTIFIC CP?

The financial health rating of KEWAUNEE SCIENTIFIC CP (KEQU) is 5 / 10.


Is the dividend of KEWAUNEE SCIENTIFIC CP sustainable?

The dividend rating of KEWAUNEE SCIENTIFIC CP (KEQU) is 0 / 10 and the dividend payout ratio is 0%.